Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, in EU countries, nintedanib plus docetaxel is used for patients with advanced non‐small cell lung cancer (NSCLC) after first‐line chemotherapy. Here, we report a case of advanced NSCLC in a patient wi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13437 |
| _version_ | 1818062387547209728 |
|---|---|
| author | Toshihiro Shiratori Hisashi Tanaka Chiori Tabe Junichiro Tsuchiya Yoshiko Ishioka Masamichi Itoga Kageaki Taima Shingo Takanashi Sadatomo Tasaka |
| author_facet | Toshihiro Shiratori Hisashi Tanaka Chiori Tabe Junichiro Tsuchiya Yoshiko Ishioka Masamichi Itoga Kageaki Taima Shingo Takanashi Sadatomo Tasaka |
| author_sort | Toshihiro Shiratori |
| collection | DOAJ |
| description | Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, in EU countries, nintedanib plus docetaxel is used for patients with advanced non‐small cell lung cancer (NSCLC) after first‐line chemotherapy. Here, we report a case of advanced NSCLC in a patient with IPF successfully treated with nintedanib monotherapy. A 69‐year‐old man was diagnosed with NSCLC complicated by IPF. After three lines of chemotherapy, he still had progressive disease. Because his IPF had also progressed, requiring supplemental oxygen, we decided to start best supportive care and introduced nintedanib to treat his IPF. One month later, we observed a partial remission of the primary tumor and pleural disseminations without severe adverse events. Nintedanib monotherapy might therefore be an effective therapeutic choice for NSCLC in patients with IPF who are unable to tolerate cytotoxic chemotherapy. Key points Efficacy of nintedanib administered in a NSCLC patient with IPF. Nintedanib monotherapy might be a therapeutic option for NSCLC patients with IPF who are unable to tolerate chemotherapy. |
| first_indexed | 2024-12-10T14:03:24Z |
| format | Article |
| id | doaj.art-ab46f054ba6347cc9dcdb5ca35746e77 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-10T14:03:24Z |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-ab46f054ba6347cc9dcdb5ca35746e772022-12-22T01:45:45ZengWileyThoracic Cancer1759-77061759-77142020-06-011161720172310.1111/1759-7714.13437Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature reviewToshihiro Shiratori0Hisashi Tanaka1Chiori Tabe2Junichiro Tsuchiya3Yoshiko Ishioka4Masamichi Itoga5Kageaki Taima6Shingo Takanashi7Sadatomo Tasaka8Department of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanHealth Administration Center Hirosaki University Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University School of Medicine Graduate School of Medicine Hirosaki JapanNintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, in EU countries, nintedanib plus docetaxel is used for patients with advanced non‐small cell lung cancer (NSCLC) after first‐line chemotherapy. Here, we report a case of advanced NSCLC in a patient with IPF successfully treated with nintedanib monotherapy. A 69‐year‐old man was diagnosed with NSCLC complicated by IPF. After three lines of chemotherapy, he still had progressive disease. Because his IPF had also progressed, requiring supplemental oxygen, we decided to start best supportive care and introduced nintedanib to treat his IPF. One month later, we observed a partial remission of the primary tumor and pleural disseminations without severe adverse events. Nintedanib monotherapy might therefore be an effective therapeutic choice for NSCLC in patients with IPF who are unable to tolerate cytotoxic chemotherapy. Key points Efficacy of nintedanib administered in a NSCLC patient with IPF. Nintedanib monotherapy might be a therapeutic option for NSCLC patients with IPF who are unable to tolerate chemotherapy.https://doi.org/10.1111/1759-7714.13437Idiopathic pulmonary fibrosislung cancernintedanib |
| spellingShingle | Toshihiro Shiratori Hisashi Tanaka Chiori Tabe Junichiro Tsuchiya Yoshiko Ishioka Masamichi Itoga Kageaki Taima Shingo Takanashi Sadatomo Tasaka Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review Thoracic Cancer Idiopathic pulmonary fibrosis lung cancer nintedanib |
| title | Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review |
| title_full | Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review |
| title_fullStr | Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review |
| title_full_unstemmed | Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review |
| title_short | Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review |
| title_sort | effect of nintedanib on non small cell lung cancer in a patient with idiopathic pulmonary fibrosis a case report and literature review |
| topic | Idiopathic pulmonary fibrosis lung cancer nintedanib |
| url | https://doi.org/10.1111/1759-7714.13437 |
| work_keys_str_mv | AT toshihiroshiratori effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT hisashitanaka effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT chioritabe effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT junichirotsuchiya effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT yoshikoishioka effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT masamichiitoga effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT kageakitaima effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT shingotakanashi effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview AT sadatomotasaka effectofnintedanibonnonsmallcelllungcancerinapatientwithidiopathicpulmonaryfibrosisacasereportandliteraturereview |